Brain Tumours

Bevacizumab

• Only low risk for CNS hemorrhage in patients with NSCLC and brain mets who are treated with bevacizumab • Potentially strong anti-edema activity • Bevacizumab alone or in combination with chemotherapy in patients with brain mets from NSCLC: • Median PFS: 7.8 months • Median OS: 14.1 months • WBRT + bevacizumab in patients with brain mets (REBECA): • Safe, but clinical benefit remains unclear

Socinski et al. J Clin Oncol 2009 De Braganca et al. J Neurooncol 2010 Lévy et al. Ann Oncol 2014